Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Joseph P. Lyssikatos, Chief Scientific Officer of Enliven Therapeutics, reported selling 12,500 shares of common stock on June 20, 2025, at a weighted average price of $21.3966 per share (ranging from $21.1228 to $22.0249), resulting in an approximate transaction value of $267,458.
Key details of the transaction:
- The sale was executed according to a Rule 10b5-1 trading plan established on November 15, 2024
- Following the transaction, Lyssikatos maintains indirect beneficial ownership of 965,188 shares through The Lyssikatos Revocable Trust 12/15/2011, where he serves as trustee
- The transaction was reported via Form 4 filing on June 24, 2025
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
FAQ
How many Bitwise MARA Option Income Strategy ETF (IMRA) SEC filings are available on StockTitan?
StockTitan tracks 29 SEC filings for Bitwise MARA Option Income Strategy ETF (IMRA), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.
When was the most recent SEC filing for Bitwise MARA Option Income Strategy ETF (IMRA)?
The most recent SEC filing for Bitwise MARA Option Income Strategy ETF (IMRA) was filed on July 21, 2025.